Stock Ratings / Health Care / PAHC / financials

GPCR (42) OCUL (37) INVA (75) ETON (62) ⌘ Pro Terminal →

Phibro Animal Health Corporation (Class A) (PAHC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$38.86 +2.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $1.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.6%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PAHC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$80.1M (6.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $977.9M

FY24

Rev $1.02B

FY25

Rev $1.30B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.30B	30.9%	8.5%	$48.3M	$80.1M	9.9%
FY 2024	$1.02B	30.8%	5.2%	$2.4M	$87.6M	5.2%
FY 2023	$977.9M	30.9%	7.3%	$32.6M	$13.3M	9.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PAHC)

✓Walkthrough of PAHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.93%⚡ TESTING RESISTANCE

2026-10-30O $39.38H $39.95L $38.49C $38.86VOL 182.8K

RES: $40.91SUP: $34.09SMA50: $36.99SMA200: $41.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAHC Butterfly Map → + Track PAHC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)

Health Care Rank #108 of 1016 ⚔️ GPCR vs PAHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAHC vs. GPCR, OCUL, INVA, ETON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #108 by composite RQD confidence (68/100, grade C+) and #300 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PAHC at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAHC ACTIVE Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	Benchmark Subject
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-pahc →
OCUL Ocular Therapeutix Inc.	D-	37/100	—	87.3%	-35.0%	+0.27%	$1.61B	/ocul-vs-pahc →
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-pahc →
ETON Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-pahc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.30B	$48.3M	$80.1M	$80.1M	$1.41B	$603.6M
FY2024 (FY)	2024-06-30	$1.02B	$2.4M	$87.6M	$87.6M	$1.29B	$622.9M
FY2023 (FY)	2023-06-30	$977.9M	$32.6M	$13.3M	$13.3M	—	—

3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $38.86 (+2.59% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, PAHC ranks #108 in composite RQD confidence.

How does PAHC compare to GPCR and OCUL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable C+ (68/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, GPCR (Structure Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B) and OCUL (Ocular Therapeutix Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PAHC?

Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?

PAHC last traded at $38.86 (+2.59% on volume of 100,844 shares), positioning the stock +5.06% above its 50-day simple moving average ($36.99) and -5.82% below its 200-day simple moving average ($41.26). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.3% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.6% ($35.91 to $41.81).

PAHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Phibro Animal Health Corporation (Class A) (PAHC)?

In FY 2025 (10-K), PAHC converted $1.3B of revenue into a 30.9% gross margin, 8.5% operating margin, and $80.1M in free cash flow (6.2% FCF margin).

Direct Sub-Reports: PAHC RQD Cockpit PAHC 12M Forecast PAHC Earnings & Move PAHC Dividends & DRIP PAHC Insiders & 13F PAHC Whale Options PAHC Profit Sankey PAHC News & Why